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Understanding molecular 
consequences of putative 
drug resistant mutations in 
Mycobacterium tuberculosis
Stephanie Portelli1, Jody E. Phelan  2, David B. Ascher1, Taane G. Clark  2,3 & 
Nicholas Furnham2
Genomic studies of Mycobacterium tuberculosis bacteria have revealed loci associated with resistance 
to anti-tuberculosis drugs. However, the molecular consequences of polymorphism within these 
candidate loci remain poorly understood. To address this, we have used computational tools to quantify 
the effects of point mutations conferring resistance to three major anti-tuberculosis drugs, isoniazid 
(n = 189), rifampicin (n = 201) and D-cycloserine (n = 48), within their primary targets, katG, rpoB, and 
alr. Notably, mild biophysical effects brought about by high incidence mutations were considered 
more tolerable, while different structural effects brought about by haplotype combinations reflected 
differences in their functional importance. Additionally, highly destabilising mutations such as alr 
Y388, highlighted a functional importance of the wildtype residue. Our qualitative analysis enabled us 
to relate resistance mutations onto a theoretical landscape linking enthalpic changes with phenotype. 
Such insights will aid the development of new resistance-resistant drugs and, via an integration into 
predictive tools, in pathogen surveillance.
Tuberculosis disease (TB), caused by bacteria in the Mycobacterium tuberculosis complex, continues to have a 
profound impact on global health. In 2015, TB was responsible for infecting 10.5 million new patients, and taking 
1.4 million lives1, being the foremost cause of mortality from a single infectious agent. While HIV co-infection 
and immigration play important roles in disease re-emergence, drug resistance remains an important but poorly 
understood driver of disease transmission2,3, and threatens disease control. Resistance arises from evolutionary 
selective pressure on M. tuberculosis after years of the same-antibiotic re-exposure, patient non-compliance to 
the long strict drug regime, and a lack of approved and available anti-TB therapies3. It is further exacerbated as 
the latest drugs, such as bedaquiline and delamanid, are reserved as last line add-on drugs4 for fear of emerging 
resistance.
Different M. tuberculosis strains have been observed to be both mono- and poly-resistant to current drug 
regimens, where the latter present a higher risk for treatment failure5. Prominent classes of poly-resistant TB 
strains include: multi-drug resistant TB (MDR-TB), which are resistant to at least isoniazid and rifampicin first 
line drugs, and extensively drug resistant TB (XDR-TB), which are additionally resistant to at least one fluoro-
quinolone and one injectable second line drug1. Resistance in M. tuberculosis may occur genetically or pheno-
typically, and is often an interplay between the two mechanisms6. Phenotypic resistance is a result of changes in 
gene expression via epigenetic changes and transcriptional regulation, while genetic resistance principally is via 
acquired genetic mutations, since horizontal gene transfer via plasmids does not occur5,7.
Distinctive mechanisms by which resistance is achieved have been described for mycobacteria including 
M. tuberculosis. Intrinsic resistance can manifest in several ways including changes to the cell wall permeabil-
ity. This can occur through using alternative enzymes involved in cell wall biosynthesis, such as the expression 
of a second class of transpeptidases that form non-classical linkages between peptides that make up the cell 
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wall leading to resistance in ß-lactam antibiotics8. In addition, hydrophilic agents often use porins to cross the 
outer membrane as the lipid membranes of mycobacteria generally have very low permeability for these agents9. 
The loss of such porins in mycobacteria has shown to drastically increase resistance to hydrophilic antibiot-
ics10. As well as low permeability of the cell wall, the other major system contributing to intrinsic resistance are 
active efflux pumps that transport antibiotics out of the cell. A well-studied exampled in M. tuberculosis is the 
increased transcription of jefA, that leads to increased resistance to isoniazid, ethambutol and streptomycin11. 
This increased expression, in clinical strains, is a result of induction in response to antibiotic stress12. The impor-
tance of efflux pumps has been shown through the development of pump inhibitors that can restore susceptibility 
in resistant strains13. Another intrinsic route to resistance is though modification by acetylation or methylation of 
either the antibiotic or its target to inhibit interaction or recognition14.
A major route to resistance is acquired resistance principally via genetic polymorphism or mutations, includ-
ing single nucleotide polymorphisms (SNPs), insertions and deletions (indels) and occasionally large dele-
tions in genes coding for drug-targets or -converting enzymes in the M. tuberculosis genome (size 4.4 Mbp)7. 
Pharmacologically, these mutations may manifest resistance via different mechanisms, affecting drug activation 
in the case of prodrugs, its entry to the target via drug permeability, or the drug target itself7,15. These geneti-
cally acquired mechanisms are influenced by factors such as: the genetic differences between lineages and espe-
cially differences in mutation rates16; epistatic interactions between mutations within the genetic background of 
M. tuberculosis17; and the dynamics within a clonal population that lead to competition within a host between 
sub-populations possessing emergent resistance associated mutations14,18.
An understanding of the molecular consequences of these mutations can provide valuable insight into how 
resistance develops and the pre-emptive identification of likely resistance mutations. Here we focus on the 
SNPs associated with resistance to two core first-line drugs, isoniazid and rifampicin, and the second-line drug 
D-cycloserine. The mechanisms of these drugs are broadly known. Isonazid is a compound that inhibits mycolic 
acid biosynthesis by binding to an enoyl-acyl carrier protein reductase encoded by the inhA gene. It is a pro-drug, 
which is activated by a catalase-peroxidase enzyme encoded by katG19,20. Most SNPs causing isoniazid drug resist-
ance are mapped onto the katG gene, and lead to a reduction or full inhibition of activity5. Rifampicin is a sem-
isynthetic antibiotic that binds to the RNA polymerase β subunit encoded by rpoB, inhibiting transcription21,22. 
Most rifampicin resistant mutations are confined to the rpoB gene21,22, within a 27 residue (81 bp) region known 
as the Rifampicin Resistance Determining Region (RRDR)23. Whereas, D-cycloserine blocks bacterial growth by 
inhibiting two enzymes involved in D-Alanine metabolism and peptidoglycan biosynthesis, including alanine 
racemase, which is encoded for by the alr gene. It is thought that enzyme overexpression leads to D-cycloserine 
resistance7.
Using a suite of structural bioinformatics tools we sought to evaluate the structural and biophysical effects 
of putative resistance SNPs in the alr (D-cycloserine), katG (isoniazid) rpoB (rifampicin) genes. In particular, 
we model the effects of these SNPs within their environments in protein drug targets alanine racemase, catalase 
peroxidase and RNA Polymerase-β, respectively. Using this approach we successfully identified the molecular 
mechanisms of known resistance mutations. While we have previously observed correlations between structural 
features and the resistance they confer24, a broader systematic analysis of the structural and biophysical changes 
leading to resistance will greatly facilitate their integration into genotypic phenotyping programmes. The pro-
teomic structural methods decribed have the ability to inform our understanding of how clinically observed vari-
ants lead to resistance, as well as guide the development of compounds less prone to resistance25–27. Therefore the 
proteome-wide scaling up of our approach has the potential to identify new drug targets and forms of resistance.
Results
SNPs and protein structures. SNP data for 6,465 M. tuberculosis clinical isolates with drug susceptibility 
testing using 1st line and 2nd line drugs were available (described elsewhere)24. The isolates represented the four 
main lineages (1–4) of M. tuberculosis, and were sourced from over 20 countries across 5 continents, thereby rep-
resenting global diversity. Drug resistance phenotypes for the isolates varied from susceptible (n = 4,451, 68.8%), 
resistant to at least one drug (n = 763, 11.8%), MDR-TB (n = 973, 15.1%) and XDR-TB (n = 278, 4.3%). Many 
of the isolates have been experimentally measured to establish the minimum inhibitory concentration (MIC) of 
drug required for resistance phenotype. SNPs with non-synonymous mutations in the katG (n = 189) and rpoB 
loci (n = 201) collectively associated with MDR-TB (isoniazid and rifampicin), and within the alr gene (n = 48) 
associated with D-cycloserine resistance were analysed (Supplementary Fig. 1). These SNPs have been identified 
in recent GWAS studies24,28 with the majority (80%) not described in functional studies. The crystal structure 
of apo-alanine racemase is available as PDB entry 1XFC29. The crystal structure of apo-catalase peroxidase is 
available as PDB entry 1SJ2, and described elsewhere19. The crystal structure of RNA Polymerase-β was inferred 
through homology modelling. The analytical strategy is described in Supplementary Fig. 2 and the Methods 
section. In brief, GWAS data and protein structural understandings were used to map SNPs onto protein struc-
tures and measure their effects on protein and complex stabilities, and ligand and nucleic acid affinities using the 
mCSM suites. Based on these measures, a better understanding of molecular mechanisms was achieved based on 
the predominant functions affected by each mutation. A general overview of all properties and their respective 
variabilities is depicted in Fig. 1a. As expected: correlation between accessible surface area and volume exists; a 
weak correlation between mCSM-lig measures and distance from the active site is observed30; and other measures 
showing no correlations to each other (see Supplementary Fig. 3). Trends for the separate proteins are depicted 
in Fig. 1b, where differences between the three proteins normalised averaged values were intriguingly similar. 
Notably, the main difference between targets was between affinity and respective distance, and was attributed to 
the different complexities ranging from small protein Alr to large protein RpoB. Residues having multiple SNPs 
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were identified and linked to drug resistance31. These were not limited to the active site, showing that drug resist-
ant hotspots need not directly interfere with ligand binding.
All sites having more than two SNPs were therefore considered as hotspots in our analysis, with sites having 
only two SNPs could be thought of ‘budding’ resistance hotspots (Supplementary Fig. 1). Within alr, four mul-
tiple SNP sites having two SNPs each were identified: Thr75, Asp139, Tyr388 and Arg397. The katG gene had 
22 multiple SNP sites, the most prominent being active site residue Ser315 which had five variants. Its mutation 
to threonine (S315T) was highly associated with drug resistance24, and related to the formation of an isoniazid 
derivative unable to form INH-NAD5. In rpoB, 33 sites had multiple SNPs, 13 of which were at the RRDR and 
within the active site. The most prominent residue of these was His445, also present at the RRDR and active site, 
for which seven different mutations were identified.
Most phenotypically resistant mutations acted allosterically. The mutations within our three tar-
get proteins were distributed throughout their structures, and were not limited to the active site despite showing 
the drug resistant phenotype. Only 18% of resistant variants were present within 10 Å of the active site, while 
the remaining 82% were present at distal sites. Within alr, 39.6% of the 48 mutations were within 10 Å of either 
protomer’s (of the homodimer) active site and 58.3% within 10 Å of a protein-protein interface Supplementary 
Table 1). The properties analysed were evenly distributed, as 33.3% of all mutations directly affected ligand affin-
ity, 29.2% affected complex stability via protein-protein interactions, and 31.3% were related to protomer stability 
(Fig. 2). It is thought that this even distribution is due to the small number of mutations identified, the compact 
structure of the homodimer and the presence of the active site at the protein-protein interface, where different 
mechanisms imparted by local mutations may equilibrate.
Within katG, 14.8% of the 189 mutations were within 10 Å of the active site, while 30.7% were within 10 Å of 
the protein-protein interface (Supplementary Table 2). The major property affected by variants was protein stabil-
ity (55.5%), followed by protein-protein interactions as a measure of complex stability (26.5%) and ligand affinity 
(12.7%; Fig. 2). Since katG is not an essential protein for M. tuberculosis32, but the principle activator of isoniazid, 
a large proportion of protomer destabilising mutations is thought to impart a drug resistance phenotype through 
a direct instability of the activating protein, which does not come at a high bacterial fitness cost. For the purposes 
of our analysis, bacterial fitness in the presence of the drug is considered to be the ability of the M. tuberculosis 
clinical isolates to survive following administration of a drug regimen observed clinically and supported using 
standard experimentally measured minimum inhibitory concentration (MIC) values, where available.
For target rpoB, 29.4% of the 201 mutations analysed were within 10 Å of the active site; 30.3% of all muta-
tions were within 10 Å of any type of nucleic acid – whether single stranded RNA, single stranded DNA, double 
stranded DNA or DNA/mRNA transcript and 82.6% were within 10 Å of another RNA polymerase complex 
subunit (Supplementary Table 3). The most prominent properties affected by the mutations were protein-protein 
interactions (48.3%) with other RNA polymerase subunits, followed by ligand affinity (19.4%), protomer stability 
(18.4%) and protein-nucleic acid interactions (12.4%; Fig. 2).
Despite the large number of complex destabilising mutations, we know that compensatory mutations are 
commonly observed within the other subunits31,33, which stabilise and retain the function of the full complex. 
However, as the protein-protein interface comprises both the active site and the nucleic acid binding site, variants 
affecting local conformation leading to a loss in complex stability, may affect other properties directly leading to 
drug resistance.
Figure 1. (a) General correlations between biophysical (DUET, mCSM-lig, mCSM-PPI) and physicochemical 
(Accessible Surface Area, Volume, Mass, Charge, Hydrogen bond donors and acceptors) properties of all 
mutations in this study. The standard deviation for all properties is shown as a shaded area – where the most 
prominent are changes in hydrogen-bond forming moieties and distances to active site and protein-protein 
interface. (b) Correlations between properties for each target separately: alr in yellow, katG in orange and rpoB 
in green.
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Mutational effects were mostly imparted via steric or electrostatic changes. At the protein level, 
local changes in size or charge upon mutation are thought to contribute to conformational changes, leading to a 
difference in protein stability and interactions with other proteins, nucleic acids and ligands. One such mutation 
is E373G within alr (see Fig. 3). The large steric difference in residue size upon mutation to glycine (accessible sur-
face area: −99 Å2), along with a loss of negative charge, has led to a large loss of protein stability (Supplementary 
Table 1). At the molecular level, this mutation likely disrupts local interactions involving the wildtype residue 
glutamic acid, causing a local conformational change. Changes in amino acid properties upon mutation were 
a notable trend throughout the SNPs. Of all the 438 mutations within the three structures, 34.9% exhibited a 
change in charge, which is judged to affect local interactions with neighboring residues. When considering the 
change in accessible surface area (ASA; Supplementary Fig. 4) as a measure of residue size, 63.9% of all variants 
in our dataset exhibited a modulus difference of less than 50 Å2. This skewed distribution is considered to be a 
direct limitation of protein fitness. In the context of protein folding, a large difference in ASA upon mutation is 
deemed to disrupt local conformation and stability, in turn affecting the overall protein fold. Although we relate 
this disruption to a protein fitness penalty, other mutations are thought to compensate for these penalties, ulti-
mately restoring protein fitness32. However, these conformational changes, though ultimately not affecting overall 
protein fold, may still lead to functional changes. Therefore, is thought that differences in drug response, coupled 
with an improved protein fitness via compensatory stabilising mutations, leads to the development of the drug 
resistance phenotype (Fig. 4).
Frequently occurring mutations did not confer extreme changes in parameters. The highest 
incidence GWAS mutations within alanine racemase (L113R, Supplementary Table 1) catalase peroxidase (R463L 
and S315T, Supplementary Table 2) and RNA polymerase-β (S450L, Supplementary Table 3) conferred relatively 
mild changes to the effects measured when considered individually. When considering these effects in relation 
to protein fitness, these mutations are deemed to be nearly neutral, due to a lower effect on protein stability. This 
lower effect leads to a lower protein fitness penalty, which is thought to lead to their enrichment within a popu-
lation. Therefore, within an energy landscape (Fig. 4c) these mutations are considered to reside at an ‘optimised 
local minimum’, closer to the wild type global minimum. Due to this lower protein fitness penalty, these muta-
tions are also thought to confer a good fitness at the bacterial fitness level, with an improved bacterial fitness in 
the presence of drug, due to their drug resistance phenotype.
The katG mutation R463L had mild to moderate destabilising (therefore showing a reduction in free energy 
values in the measures tested) effects despite its high incidence (40.6%), however it showed a lower association 
with drug resistance (p-value: 6.75 × 10−1) than S315T (p-value: 6.60 × 10−1)34 because R463L is a lineage-specific 
mutation, which was controlled for in the regression-based analysis. While R463L seems to have a higher fitness 
penalty than expected for its frequency, this mutation is part of a number of haplotype combinations (described 
later in further detail). It is therefore postulated that these secondary mutations that combine with R463L com-
pensate for this fitness penalty, and enable the enrichment of the mutation within the bacterial population (Fig. 4). 
The alr high frequency mutation L113R is another exception to the nearly neutral concept, as it showed highly 
destabilising effects on both ligand affinity and protein stability. These values may explain why the incidence of 
this mutation, though the highest in its subset (0.57%), are very low compared to other high incidence mutations 
Figure 2. Distribution of mutations within alanine racemase (alr; a), catalase peroxidase chain A (katG; b) and 
RNA Polymerase β-subunit (rpoB; c). Mutations labelled according to main mechanism: ligand affinity (pink), 
protein-protein interactions (teal), protomer stability (blue) and unclassified (charcoal grey).
www.nature.com/scientificreports/
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(R463L: 40.6%, S315T: 18.5%, S450L: 13.5%). Both exceptions (R463L in katG and L113R in alr) are associated 
with a change in electrostatic properties, considered to disrupt the local conformation and thereby effect protein 
folding.
On average, the effect of these four high incidence mutations on protein stability was mildly destabilising 
(DUET average: −0.43 kcal/mol; DUET median: −0.285 kcal/mol), while that of lower incidence mutations was 
highly destabilising (DUET average: −1.01 kcal/mol; DUET median: −0.939 kcal/mol). When considering steric 
changes for these high incidence variants, only rpoB mutation S450L had an ASA difference larger than 50 Å2. 
While this was outside the majority of cases, a large change in ASA (78 Å2) for this residue could be attributable 
to compensatory mutations occurring in RNA polymerase-β‘ subunit (rpoC)33, which allow for steric difference. 
Notably, the rpoC mutation V483G (modulus difference in ASA: 80 Å2) has been identified as a compensatory 
mutation for S450L33, which cancels out the change in ASA. In turn, this is considered to optimise the local 
energy minimum at this residue locus (Fig. 4c), thereby increasing bacterial fitness.
Finally, conservation scores from ConSurf34 for the frequent mutations showed that L113R (−0.925; alr), 
S315T (−0.834; katG) and S450L (−0.771; rpoB) had a slow evolution rate (denoted by a negative value), and 
were therefore highly conserved. On the other hand, R463L (0.225; katG) had a fast evolution rate (denoted by a 
positive value), showing a less conserved site. We relate these scores to the higher destabilising effects exhibited 
by R463L when compared to its high frequency counterparts, and a lower association with INH resistance when 
compared to S315T. We consider high changes (>±1.00 kcal/mol) in mCSM30,35 and DUET36 predicted ∆∆G to 
be unlikely to be stable enough to be passed on from one generation to another, resulting in a lower population 
incidence. Moreover, we attribute large steric (>50 Å2) changes to a local instability, that is unlikely to be toler-
ated without external, compensatory mutations. The conservation scores further highlight our observations, as 
the mutations at these highly conserved residues were also related to drug resistance in GWAS (L113R p-value: 
Figure 3. Steric clashes (c red) introduced upon mutation in alr when Glu373 (a,b accessible surface area: 
188.42 Å2) was mutated to Gly (c accessible surface area: 89.41 Å2). (d) D-Cycloserine(DCS)- pyridoxal 
5′-phosphate (PLP) interaction with Y388 at the alanine racemase active site. Lys66, the original residue 
interacting with PLP, shown in olive green. Mutations labelled according to property: ligand affinity (pink), 
protein-protein interactions (teal), protomer stability (blue) and unclassified (charcoal grey).
www.nature.com/scientificreports/
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6.44 × 10−17, S450L p-value: 2.85 × 10−10 2). More tolerated mutations are retained within the population via an 
evolutionary selective pressure - drug exposure, and therefore results in the high frequency mutations within a 
GWAS analysis24. While the effect of drug resistant mutations on bacterial fitness and virulence is still debatable37, 
we relate the above tolerable ∆∆G values of frequent mutations to a low fitness penalty for M. tuberculosis strain 
survival (Fig. 4).
Mildly stabilising mutations may confer local fitness advantages. We have classified our pro-
tein variant subsets depending on the most prominent destabilising effect imparted, considering ligand affinity, 
nucleic acid affinity, complex stability (as protein-protein interactions) and protomer stability in a sequential 
order. As a result, a minority of mutations within each subset remained residual (denoted as ‘unclassified’), as they 
did not confer negative enthalpic effects, but mild overall positive effects. Similarly to the high frequency muta-
tions described above, unclassified mutations are also considered to be nearly neutral, but are thought to have an 
opposite role via a mildly stabilising effect. In general, all unclassified mutations mapped within a 5 Å distance to 
destabilising mutations and described in more detail below. Despite a lack of GWAS evidence showing haplotype 
combinations including these unclassified mutations, we associate the overall positive effects to a compensatory 
protein fitness measure (Fig. 4) for neighbouring destabilising mutations. In turn, this enables compensatory 
evolution, enriching resistant mutations within a bacterial population, as previously described38.
Three alr mutations (T75M, A217V and T401I; Supplementary Table 1) remained unclassified as per our 
analysis. All three mutations were present at the solvent accessible region of the protein, and far away (>10 Å) 
from the interacting regions. Notably, mutation A217V was close to (<5 Å) A212D and F215V, which were highly 
destabilising for protomer stability. Theoretically, it is thought that A217V improves the fitness of these close 
Figure 4. A theoretical bacterial fitness plot in the absence (a) and presence (b) of drug, running in parallel 
with a theoretical protein energy plot (c) showing different levels of protein minima. Changes in bacterial fitness 
in the presence of the drug is approximated by the changes clinically observed to susceptibility and supported, 
where available, by experimentally measured minimum inhibitory concentration (MIC) values from susceptible 
to degrees of resistance. The ‘Global Minimum’ refers to the overall energy of the protein. This minimum is 
thought to be higher in the mutant protein when compared to the wildtype, resulting in a lower protein fitness. 
However, the mutant protein confers a higher cellular fitness to that of the wildtype when subjected to drug 
selection pressure. (b) ‘Local Minimum’ refers to the local changes imparted by low frequency mutations, while 
‘Optimised Local Minimum’ is an improved local minimum brought about by high frequency mutations, or 
concomitant mutations. As an example of values that can attributed to this schematic e.g. katG mutations R463L 
and S315T: the change in protein energy is −0.215 and −0.154 kcal/mol respectively; the change in bacterial 
fitness in the presence of the drug is 0.15 and 2.7 respectively as measured by MIC.
www.nature.com/scientificreports/
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mutations by improving a local minimum (Fig. 4c), however, there was no GWAS evidence of these mutations 
occurring concomitantly. A similar scenario is applicable to T401I, which is close to variant A38V, which is 
moderately destabilising for protomer stability. Mutation T75M was not present close to any other mutation in 
our dataset, but was at a polymorphic site also mutated to alanine. As this residue was not within an interacting 
distance to the drug or the interface, a possible mechanism of resistance is a compensatory action against unfa-
vourable closeby mutations thereby maintaining a local protein minimum (Fig. 4c). We relate an improvement in 
local minima to an increased protein and bacterial fitness, especially in the presence of the drug (Fig. 4b).
Within katG, 5.8% (S211N, D259Y, E452Q, T475I, S481L, D511N, E523K, Q525P, K557N, L598R and G630V) 
of mutations remained unclassified according to our analysis. All mutations are present at or close to the solvent 
accessible region and within 5 Å of highly destabilising mutations (Supplementary Table 2). It is thought that 
these unexplained favorable effects imparted via these mutations may cancel out neighbouring disruptive muta-
tions, reducing their fitness penalty to a more tolerable energy minimum (Fig. 4c). Notably, within this protein, 
most of the unexplained mutations (except S211N and D259Y) are present at the C-terminus, surrounded by 
predominantly protomer destabilising mutations. Hence, the protomer stabilising nature of these unclassified 
mutations may also help restore the local protein fold, increasing protein fitness and overall bacterial fitness.
Only 1.5% of rpoB mutations (E66K, D259N and T676A; Supplementary Table 3) remained unclassified fol-
lowing our analysis. E66K is present within the solvent accessible surface, within 5 Å of variant A69P which dis-
rupts complex stability. D259N is also at the solvent accessible surface, with no other mutations within 5 Å. T676A 
is present within 10 Å of rifampicin binding, and within 5 Å of mutations S672Y and G675D that are highly 
destabilising for protomer stability, along with H1028R, which affects ligand affinity. The mildly stabilising effect 
of T676A may help to cancel out local protein instability at this region and maintain a local energy minimum 
(Fig. 4c), leading to the enrichment of the drug resistant mutations within the bacterial population, and enabling 
bacterial fitness in the presence of rifampicin (Fig. 4b).
Haplotype combinations exhibit different means of achieving resistance concomitantly. The 
role of secondary concomitant mutations have been previously described as having a stabilising role within a 
protein structure, in order to restore a fitness penalty imparted by highly destabilising mutations39–41. Within 
our fitness plot (Fig. 4) these concomitant haplotype mutations are thought to improve the local protein energy 
minimum, leading to the improvement of the bacterial population fitness, particularly in the presence of the drug.
Three haplotype combinations were identified within the katG gene (Supplementary Table 4), where the most 
prominent combined effects were a reduction in INH affinity and complex stability. Mutation R463L, located at 
the solvent accessible C-terminus, was present in all haplotypes. Its combination with W191R at the N-terminal 
protein-protein interface, and S315T/N at the active site is thought to be a means of achieving different resistance 
mechanisms concomitantly (Fig. 5a). Moreover, W191R and S315T/N are thought to compensate the effects 
of R463L, and enrich it within the population. On the other hand, the eight rpoB haplotypes (Supplementary 
Table 5) identified were more dispersed, and included residues having multiple SNPs: S450, V970, R827, P45 
and D435 (Fig. 5b). Most haplotypes occurred coupled to S450L, the most frequently occurring mutation for this 
protein. Again, it is thought that these haplotypes may help enrich S450L within the population by counteracting 
any steric and consequentual conformational changes imparted via S450L (change in ASA: 78 Å2). Mutations cou-
pled to L452P were present both at the active site (D435G, Fig. 5a), and at the β′ interface (I1106T and H1028R, 
Fig. 5b). L452P combinations were moderately destabilising for protomer stability, ligand affinity and complex 
affinity, while they were mild to moderately stabilising for nucleic acid affinity. From those coupled with S450L, 
only I488V is in close geographical proximity to the active site (Fig. 5b), which explains the highly destabilising 
effect on nucleic acid affinity occurring for this combination. Q975H and V998A are at the α1 interface, L731P 
lies at the interface between all four subunits, and R827C is close to the DNA binding locus (Fig. 5b). From these 
observations, we conclude that a close topological proximity of concurrent mutations is thought to enable local-
ised effects, while the combination with external mutations ensures different mechanisms lead to drug resistance 
concurrently.
The prominent alr Tyr388 mutation. Certain loci within our targets are thought to be at strategic posi-
tions, as reflected in their spectrum of effects. The most pronounced example of a strategic locus in our dataset 
was residue Y388 within alanine racemase. This residue was confirmed by our ConSurf34 analysis to be highly 
conserved, indicating a potential functional significance for alr. Properties for drug resistance, as discussed above, 
are exemplified in Y388. Multiple mutations at the site (Y388D/C) show linkage to a developing mutational hot-
spot for drug resistance31. Both SNPs at this locus are the most prominently disruptive within alanine racemase 
(Supplementary Table 1), exhibiting destabilising effects across all the enthalpic measurements taken. Residue 
Y388 is situated within the active site entryway and forms a 2.7 Å gate with Y295 of the opposite chain29. The 
smaller aspartic acid and cysteine mutant residues are thought to destabilize this gate, via a loss of hydrophobic 
inter-tyrosine interactions and subsequently, protein-protein affinity. The loss of the van der Waals interaction 
between Y388 and PLP (Fig. 3d), in turn, is thought to reduce ligand stability, possibly affecting affinity.
Discussion
Genetic variants, including nsSNPs, present within drug targets and drug-activating enzymes have been identi-
fied as a main cause of drug resistance in TB7. In this study, we aimed to understand the consequences of nsSNPs, 
to better understand driving forces of drug resistance in TB. We have related mutations identified from clinical 
isolates to local molecular mechanisms, using in-silico measures of change in enthalpy. The mCSM30,35 predictions 
use graph based signatures, where inter-atomic distance patterns describe the wild-type residue environment 
directly interacting with the mutation site. Long range patterns are also considered30,35, meaning that both local 
and global effects of point mutations have been characterized. Appended to these signatures within mCSM is 
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a ‘pharmacophore count’ vector, which considers the atom changes from wildtype upon mutation30,35. These 
features are present within all mCSM30,35 tools used, while DUET36 uses a consensus regression score of predic-
tors mCSM-Stability35 and SDM42,43. The latter method calculates amino acid frequency substitutions within 
homologs to reach a stability score42,43. Therefore, DUET36 is thought to be a better predictor for protein stability 
upon mutation than mCSM35 alone. Through these methods, we identified how our point mutations affected 
protein stability and protein interactions with other proteins, ligands or nucleic acid44,45, and subsequently how 
these changes affected protein function44,46.
Our study focused on categorising the predominant effect of each mutation, based on distance to interacting 
site. The destabilising effects were given higher consideration in classifying mutations, since nsSNPs are usually 
related to a decrease in protein stability, or a change in protein function41 (via disruption of drug affinity, nucleic 
acid affinity or overall complex stability). This left a minority of protein stabilising variants ‘unclassified’, which 
we consider to be nearly neutral for protein fitness. Their stabilising role is thought to permit the restoration of 
the protein fold following the introduction of conformation-disrupting, unfavourable mutations in close prox-
imity (Fig. 4c). The restoration of the protein fold is thought to increase the bacterial fitness in the presence of the 
drug (as approximated by changes in clinically observed susceptibility supported by minimum inhibitory concen-
tration (MIC) values), as drug resistant mutations are stabilized and enriched within the population41 (Fig. 4a,b). 
Moreover, an increase in protein stability has been previously linked to a detrimental effect on protein dynamics 
and regulation47, which further supports their role in conferring local stability and protein fitness (Fig. 4c), despite 
not being present in any of our haplotype combinations. Since all were close to highly destabilising mutations, a 
stabilised protein conformation enables these highly unfavourable mutations to become tolerated, suggesting a 
possible mechanistic approach to achieve drug resistance.
The overall protein fitness is thought to be dependent on the extent of enthalpic measures, concomitant 
mutations, and compensatory mutations in interacting proteins (Fig. 4c). The milder effects on protein stability 
exhibited by the high frequency mutations are considered to help select for the mutation enrichment within the 
Figure 5. (a) katG haplotype combinations between R463 and W191/Ser315 residues. (b) Haplotype 
combinations occurring in rpoB. Those coupled to S450 are depicted in the purple colour scale, while those 
coupled to L452 are rendered in the orange colour scale. Mutated residues are shown as sticks, while isoniazid 
(INH) and rifampicin (RIF) are shown as spheres in cyan.
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population. High frequency mutations, along with the unclassified mutations, are deemed to be nearly neutral 
with respect to protein fitness. The ‘unclassified’ variants had mild stabilising effects, while high frequency muta-
tions had mild destabilising effects. This enabled the latter to confer drug resistance via an optimised local energy 
minimum (Fig. 4c), thereby considered to be better tolerated according to protein thermodynamics. Further to 
this, the nearly neutral nature of high frequency mutations is thought to enable their enrichment in a particular 
locus, due to an overall ‘mild impact’ imparted on protein folding and bacterial fitness, whether in the presence or 
absence of drug (Fig. 4). The more destabilising mutations are considered to confer a ‘higher impact’ on protein 
folding energy, and subsequent protein and bacterial fitness, and are deemed to be less likely tolerated. Within 
the energy fitness curve (Fig. 4) these mutations lie at the higher protein energy (Fig. 4c) and a lower bacterial 
fitness (Fig. 4a,b), but are considered to be stabilized by compensatory effects to an optimised protein energy 
minimum, leading to a higher bacterial fitness (Fig. 4a,b). These compensatory effects are thought to occur via 
concomitant mutations, either within interacting proteins e.g. RNA polymerase subunits33, or via same-protein 
haplotype combinations. Some mutations affected different properties measured due to their distances from the 
interacting surfaces. These measures are considered to collectively help enrich a mutation and bring about the 
drug resistance phenotype.
Trends in variant distribution within all three proteins studied have shown that most GWAS phenotypically 
resistant mutations were not present at the active site, meaning that the effect was brought about allosterically, 
not directly through ligand binding affinity. Allosteric effects are predominantly via confiring protomer stability 
for alr and katG, and non-ligand interaction affinities for rpoB. While we do not have the MIC values for all the 
SNPs to relate in-silico results to experimental meaures of resistance, this was the most in-depth study identify-
ing enthalpic effects of SNPs within M. tuberculosis targets catalase peroxidase, RNA Polymerase-β and alanine 
racemase to date. Through this qualitative analysis, we have observed what are considered to be fitness penalty 
measures imparted through the point mutations, where the same variant exhibits drastic enthalpic costs in one of 
the properties tested, but is compensated with balancing, favourable effects on other measures (Supplementary 
Tables 1–3). Further, haplotype sets have shown concomitant, complimentary effects, possibly to promote fitness 
of strain survival (Fig. 4). These same haplotype combinations are thought to purposely occur near to each other 
to enhance a local mechanistic effect, or at separate parts of the target to enable multiple mechanisms of resistance 
concomitantly.
Our analysis has shed light on new possible SNP hotspot Y388 within alanine racemase, which confers highly 
destabilising effects on general protein stability, and affinity for homodimer formation and D-cycloserine ligand 
binding. Within this residue, a disruption of local electrostatic bonding is thought to occur in both variants, via 
an addition of a negative charge (Y388D) or an addition of a sulphur atom (Y388C). However, the mutation to 
aspartic acid was more disruptive than that to cysteine, potentially due to the introduction of a residue having 
negative charge.
The improved understanding of mechanistic effects of drug resistant TB strains is of ultimate importance 
for the design of newer, resistance-resistant therapies, via the avoidance of drug resistance hotspots, and the 
development of machine learning approaches to predict resistance potential of SNPs. This is crucial in a disease 
state which has seen only recent introduction of newer therapies4, where poly-resistant strains have had time to 
develop, and affects millions of people worldwide every year. An understanding of mutational structural mech-
anisms can be applied to other infectious and non-infectious diseases under selective drug pressure, since the 
principles of protein structure and function are universally applicable.
Materials and Methods
Drug Targets and the SNP dataset. SNP data and association p-values were available from a GWAS 
of 6,465 clinical isolates, which had drug susceptibility test data for rifampicin, isoniazid and D-cycloserine24. 
Simultaneously we compiled a list of all the anti-TB drugs and their respective targets from the literature, and a 
search for suitable crystallographic structures was initially made in PDBe48 and RCSB49,50 databases. CHOPIN51 
and ModBase52 homology databases were used to identify homology models where crystallographic structures 
were unavailable. The complete list was ranked according to SNP p-values from the GWAS. Due to their strong 
associations with MDR-TB1,5,7 genes katG and rpoB, which transcribe catalase peroxidase and RNA polymer-
ase-β respectively were chosen, while gene alr, which transcribes alanine racemase, was selected due to lack of 
prior investigation. Within the katG gene, 6,733 clinical isolates were tested for isoniazid and 189 nsSNPs, along 
with 3 haplotype combinations were identified. Within the rpoB gene, 6,697 isolates were tested for rifampicin, 
which identified 201 nsSNPs and 8 haplotype combinations. In the case of alr, 252 clinical isolates were tested for 
D-cycloserine (DCS) susceptibility, which identified 48 nsSNPs and no haplotype combinations. These nsSNPs 
were subjected to analysis according to the workflow in Supplementary Fig. 2.
Protein Modelling. Missing residues from the alr crystal structure (PDB ID: 1XFC)29 were modelled using 
UCSF Chimera 1.1153 from the second chain in the homodimer. Both chains were kept for docking, as were 
co-crystallized water molecules present within the active site. Protein minimisation was not possible due to the 
presence of covalent linkage between residue Lys66 and PLP. Instead, Molprobity54,55 was used to assess protein 
suitability due to modelled residues, while WinCoot-0.8.356 was used to ‘regularise’ outlying residues identified 
within the structure. Prior to docking DCS-PLP, the PLP bonded to Lys66 was removed using UCSF Chimera 
1.1153.
Proteins alr and katG were present as previously described crystallographic structures, while the homology 
model of rpoB was built on templates PDB IDs: 1TWF57, 1YNN22 (holoprotein), 2A6H58, 2E2I59 and 3CQZ60 
using Schrondinger Suites v.2016.4.
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Homology modelling: RNAP complex. For use in the mCSM-PPI and mCSM-NA35 predictions, the full 
RNA polymerase complex was required. At the time of the study, the now crystallised M. tuberculosis structure 
(PDB ID: 5UHC)61 was not available, therefore a homology model was used instead. The homology model of the 
full M. tuberculosis RNAP was built using the crystallised structure of E. coli RNAP62 as a template. Homology 
models of the α1, α2, and β‘ M. tuberculosis subunits were initially searched for in CHOPIN51 and Phyre263, using 
the amino acid sequences available in Tuberculist64,65 as search queries. Models for α1 and α2 were obtained from 
Phyre263 using template PDB ID: 5I2D, while the β‘ model was obtained from Phyre263 using PDB ID 4G7O as the 
template. The ω subunit was not modelled as it did not directly interact with the β subunit, and therefore was out-
side the scope of our model. The individual subunits were aligned to the E. coli subunits62 and the co-crystallised 
DNA from the E. coli structure was modelled onto the M. tuberculosis structure62, using UCSF Chimera 1.1153. 
Upon the availability of the crystal structure PDB ID 5UHC, our modelled complex was superimposed with the 
crystallised complex using PyMol24. The two structures differed in backbone atomic positions at a root-mean 
square deviation (RMSD) value of 2.38 Å over 6596 atoms. Given the 3.8 Å resolution of the crystal, these RMSD 
values give us reasonable confidence to assume our model is of good quality as its atomic positions are within the 
margin of error of the crystal structure obtained.
Ligand Docking. The apo-protein structures of alr, katG and rpoB required docking of their respective 
ligands for further analysis using mCSM-Lig30. The ligand structures for DCS (covalently bound to pyridoxal 
5′-phosphate (PLP); DCS-PLP), isoniazid and rifampicin were obtained from holo-homolog structures PDB 
IDs 4LUT66, 5SYJ20 and 1YNN22 respectively. The first and second line drugs DCS (as DCS-PLP), isoniazid 
and rifampicin were docked within alr, katG and rpoB structures respectively, using Glide (Schrodinger Suite). 
Docking was carried out using default parameters, guided by the positions of homolog co-crystallised ligands in 
PDB entries 4LUT66 (alr), 5SYJ20 (katG) and 1YNN22 (rpoB). To facilitate analysis, DCS-PLP was only docked 
within chain A of alr, although both chains were kept for docking. While cofactor heme was kept for isoniazid 
docking within katG, cofactor PLP was docked covalently bound to DCS within alr. The best binding poses were 
chosen through an RMSD comparison with the homolog-bound ligands, and their interaction with active site 
residues through an Arpeggio67 analysis.
In silico predictions. The GWAS SNP hits were subjected to the graph-based signature algorithms: DUET36, 
mCSM-Stability35, mCSM-Lig30, mCSM-PPI35 and mCSM-NA35,68 (where applicable). Data was filtered according 
to distance from interacting site (ligand pose, protein-protein interface and nucleic acid interface), where residues 
at a distance >10 Å were excluded. These were classified according to ∆∆G numerical thresholds: highly dest-
abilising (<−1.00 kcal/mol), moderately destabilising (between −1.00 and −0.5 kcal/mol), mildly destabilising 
(between −0.5 and 0 kcal/mol), mildly stabilising (between 0 and 0.5 kcal/mol), moderately stabilising (between 
0.5 and 1.00 kcal/mol) and highly stabilising (>1.00 kcal/mol). Finally, distances to the interacting sites were also 
categorised in two: <5 Å (likely interacting) and <10 Å (possibly interacting). Conclusions were then drawn 
up based on all the factors and interaction distances. In classifying the major properties of each mutation, the 
destabilising effects were reviewed in a hierarchical manner, according to ligand affinity, nucleic acid affinity, 
complex stability (protein-protein interactions) and protomer stability. Unexplained mutations were those which 
had a stabilising effect, with no other destabilising effects to explain disruption of the wildtype.
Haplotype analysis. During haplotype analysis, we sought to calculate the enthalpic change in properties 
upon introduction of a mutation, in the presence of another mutation. Mutant proteins representing single muta-
tions were initially prepared using PyMol24 mutagenesis wizard. These were analysed using the tools described 
above. The values obtained from each haplotype variant were then averaged with the other variants in the same 
combination, in order to obtain a consensus value depicting overall effects. To calculate the value for each prop-
erty (y) and haplotype mutations A and B occurring concomitantly, we used the equation
=
+
y
y y( _ _ )
2
,haplotype
Am B Bm A
where Am_B refers to the protein mutated with variant A, followed by introduction of mutation B within the 
mCSM webtools; Bm_A refers to the protein mutated with variant B, followed by introduction of mutation A 
within the mCSM webtools.
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